Experienced in Vogt-Koyanagi-Harada Disease

Dr. Andrea B. Apolo

Internal Medicine
10 Center Dr Rm 12n226, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Vogt-Koyanagi-Harada Disease
10 Center Dr Rm 12n226, 
Bethesda, MD 
OverviewInsuranceLocationsClinical Research

Overview

Andrea Apolo is a primary care provider, practicing in Internal Medicine in Bethesda, Maryland. Dr. Apolo is rated as an Experienced provider by MediFind in the treatment of Vogt-Koyanagi-Harada Disease. Her top areas of expertise are Penile Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, and Neuroendocrine Tumor.

Her clinical research consists of co-authoring 134 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Vogt-Koyanagi-Harada Disease.

Specialties
Internal Medicine
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

10 Center Dr Rm 12n226, Bethesda, MD 20892

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug
Study Drug: Olaparib
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 1
View 2 Less Clinical Trial

134 Total Publications

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Apolo's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile